about
Two negative randomized controlled trials in lupus: now what?Association analyses confirm five susceptibility loci for systemic lupus erythematosus in the Han Chinese population.The Diagnosis and Treatment of Systemic Lupus ErythematosusNovel treatments for systemic lupus erythematosus.Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.Treatment targets in systemic lupus erythematosus: biology and clinical perspective.LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus.Apolipoprotein E Gene Polymorphisms in Saudi Patients with Systemic Lupus ErythematosusEuropean population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus.Lethal manifestations of systemic lupus erythematosus in a forensic context.Long-term renal outcome and complications in South Africans with proliferative lupus nephritis.Prevalence and incidence of systemic lupus erythematosus in South Korea.Burden of lupus on work: Issues in the employment of individuals with lupus.Systemic lupus erythematosus and infections: a retrospective study in Saudis.External Validation of the Lupus Impact Tracker in a Southeastern US Longitudinal Cohort With Systemic Lupus Erythematosus.Four cases of facial discoid lupus erythematosus successfully treated with topical pimecrolimus or tacrolimus.Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea.Clinical trials in systemic lupus erythematosus: a status report on ongoing trials.Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years.
P2860
Q34076412-E5B68BF4-90AD-455A-9CBA-4763A163C760Q35496923-8348B1B6-FCC2-420C-97AA-0106FCF6DA10Q35692998-A32DB320-EF24-4869-81AD-D7972112B14CQ36059553-76B2571D-C630-4B1C-A043-266B948C47A0Q36096756-88FBD91A-FC83-43F4-923D-263A5878AC88Q36504624-22A28614-AD84-41E0-AF4D-A7B8403FD990Q36787315-7A19B115-F0B1-4EC7-8CB7-52088EF79F0BQ36927173-A47243CB-59A9-4475-A33D-E40E5CB2AC6CQ37335908-A2EECA93-1B49-4596-ACF0-12A964EDFE20Q37838467-5FB0E41F-91EE-4E69-B3C1-AC979FF47D2BQ38073122-8E153898-94FD-4DE1-8DC1-8B560A1EC34EQ38423234-0C13045E-65DF-4A25-B4BD-149CA5B3CF42Q38968818-6EBE4CC2-9E3A-404C-BF7A-D9190C656A7EQ40440734-9F0DACFC-7844-4CC4-9859-329017C927EBQ40606314-00EA6CBD-E13D-4ADB-9A11-5DE6A3704800Q41771409-74DFFECB-07A4-4F6B-9581-929D2B88C3AAQ47143263-CE07945E-84FE-4CDE-8B57-9FCE4BAF4744Q50695802-61623742-5728-466B-BAB3-07C1630B0D28Q51835763-0458150F-F097-4810-9672-F5182C85B4A8
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Can morbidity and mortality of SLE be improved?
@ast
Can morbidity and mortality of SLE be improved?
@en
Can morbidity and mortality of SLE be improved?
@nl
type
label
Can morbidity and mortality of SLE be improved?
@ast
Can morbidity and mortality of SLE be improved?
@en
Can morbidity and mortality of SLE be improved?
@nl
prefLabel
Can morbidity and mortality of SLE be improved?
@ast
Can morbidity and mortality of SLE be improved?
@en
Can morbidity and mortality of SLE be improved?
@nl
P2093
P356
P1476
Can morbidity and mortality of SLE be improved?
@en
P2093
Anurekha Bongu
Elizabeth Chang
Rosalind Ramsey-Goldman
P304
P356
10.1053/BERH.2001.0228
P577
2002-04-01T00:00:00Z